Default object view. Click to create a custom template, Node ID: 141409, Object ID: 83606

Combination vs monotherapy in pancreatic ductal adenocarcinoma

Combination vs monotherapy in pancreatic ductal adenocarcinoma

Given the toxicity profile and efficacy results, the combination regimen of gemcitabine and capecitabine is a new standard in adjuvant care of resected pancreatic ductal adenocarcinoma (PDAC) says J. Neoptolemos. He further digs into results, presented at ASCO 2016 Annual Meeting, of combination regimen with hypoxia-activated prodrug evofosfamide and gemcitabine in previously untreated metastatic or locally advanced unresectable PDAC.

YvMXnAIixB8

Science et technologie

https://i.ytimg.com/vi/YvMXnAIixB8/sddefault.jpg

Yes